Reduced percentages and absolute counts of CD4 T cells following CY treatment has been noted in blood and spleen at days 7 and 21 post-BMT in a haploidentical mouse model, which was suggested to be a major contributing factor by which CY mediates GvHD progression (26). This evidence concerns the gene CD4 and graft versus host disease.